Depomed Inc (NASDAQ:DEPO) SVP Matthew M. Gosling sold 45,519 shares of the company’s stock in a transaction that occurred on Wednesday, March 7th. The stock was sold at an average price of $6.58, for a total transaction of $299,515.02. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Depomed Inc (NASDAQ DEPO) opened at $6.95 on Friday. Depomed Inc has a 52-week low of $4.31 and a 52-week high of $16.29. The company has a quick ratio of 0.70, a current ratio of 0.74 and a debt-to-equity ratio of 3.21.
Depomed (NASDAQ:DEPO) last issued its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.15 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $0.05. Depomed had a negative net margin of 26.92% and a negative return on equity of 45.19%. The business had revenue of $94.41 million for the quarter, compared to analysts’ expectations of $88.75 million. research analysts forecast that Depomed Inc will post -0.89 earnings per share for the current year.
DEPO has been the topic of several research analyst reports. Royal Bank of Canada set a $9.00 price objective on shares of Depomed and gave the stock a “hold” rating in a research report on Thursday, December 7th. ValuEngine cut shares of Depomed from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. BidaskClub cut shares of Depomed from a “hold” rating to a “sell” rating in a research report on Tuesday, January 23rd. Mizuho upgraded shares of Depomed from a “neutral” rating to a “buy” rating and set a $9.00 price objective on the stock in a research report on Tuesday, December 5th. Finally, Piper Jaffray Companies restated a “hold” rating and issued a $9.00 price objective on shares of Depomed in a research report on Thursday, December 7th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. Depomed has an average rating of “Hold” and an average price target of $10.14.
Depomed Company Profile
Depomed, Inc is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl).
Receive News & Ratings for Depomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Depomed and related companies with MarketBeat.com's FREE daily email newsletter.